A study in NSCLC patients showed that low systemic levels of PCSK9 (<95 ng/mL) predict a more favorable response to the PD-1 inhibitor Nivolumab and are associated with improved OS compared to patients with higher levels (>120 ng/mL) [94]. Here, PCSK9 is linked to non-small cell lung carcinoma.